BidaskClub upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a report published on Wednesday morning, BidAskClub reports.
A number of other analysts have also recently weighed in on the company. ValuEngine upgraded Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research cut Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Friday, October 11th. Cantor Fitzgerald restated an overweight rating and issued a $24.00 price target (down from $35.00) on shares of Collegium Pharmaceutical in a research note on Thursday, August 8th. Needham & Company LLC cut their price target on Collegium Pharmaceutical from $33.00 to $25.00 and set a buy rating on the stock in a research note on Wednesday, October 30th. Finally, William Blair restated a buy rating on shares of Collegium Pharmaceutical in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. Collegium Pharmaceutical has a consensus rating of Buy and a consensus target price of $24.57.
Shares of COLL stock traded up $1.96 during trading hours on Wednesday, reaching $19.96. The company had a trading volume of 1,220,900 shares, compared to its average volume of 378,932. The company has a market capitalization of $459.95 million, a price-to-earnings ratio of -16.77 and a beta of 0.52. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.20 and a current ratio of 1.25. Collegium Pharmaceutical has a 12-month low of $10.01 and a 12-month high of $19.99. The stock has a fifty day moving average of $12.16 and a 200-day moving average of $12.08.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The business had revenue of $72.94 million during the quarter, compared to analyst estimates of $74.32 million. During the same quarter in the prior year, the business earned ($0.50) earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. On average, analysts forecast that Collegium Pharmaceutical will post -0.51 EPS for the current year.
In other news, CEO Joseph Ciaffoni sold 64,821 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the sale, the chief executive officer now owns 242,276 shares in the company, valued at $4,547,520.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Hirsch sold 22,106 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the sale, the director now owns 64,223 shares in the company, valued at approximately $748,197.95. The disclosure for this sale can be found here. 8.08% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of COLL. First Quadrant L P CA increased its position in shares of Collegium Pharmaceutical by 87.2% during the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 2,089 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its position in shares of Collegium Pharmaceutical by 33.0% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 6,041 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,500 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Collegium Pharmaceutical by 1,299.5% during the third quarter. Meeder Asset Management Inc. now owns 8,495 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 7,888 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth about $98,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth about $116,000. Institutional investors and hedge funds own 92.17% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.